EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, RUA Life Sciences's enterprise value is €7.92 Mil.
RUA Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was €-2.49 Mil. Therefore, RUA Life Sciences's EV-to-EBITDA for today is -3.19.
The historical rank and industry rank for RUA Life Sciences's EV-to-EBITDA or its related term are showing as below:
FRA:AOHA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.05 Med: -3.73 Max: 62.35
Current: -3.09
During the past 13 years, the highest EV-to-EBITDA of RUA Life Sciences was 62.35. The lowest was -34.05. And the median was -3.73.
FRA:AOHA's EV-to-EBITDA is ranked worse than 100% of 479
companies
in the Medical Devices & Instruments industry
Industry Median: 15.22
vs FRA:AOHA: -3.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
RUA Life Sciences EV-to-EBITDA Historical Data
The historical data trend for RUA Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RUA Life Sciences's EV-to-EBITDA
For the Medical Devices subindustry, RUA Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's EV-to-EBITDA falls into.
RUA Life Sciences's current Enterprise Value is €7.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RUA Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was €-2.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
RUA Life Sciences's PE Ratio for today is calculated as:
RUA Life Sciences's share price for today is €0.11.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RUA Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €-0.097.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of RUA Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives its major revenue from the USA and has a presence in Europe and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AOHA has been successfully added to your 